{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:32:50Z","timestamp":1790371970877,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004082","name":"Korea Foundation for Cancer Research","doi-asserted-by":"crossref","award":["CB-2022-A-3"],"award-info":[{"award-number":["CB-2022-A-3"]}],"id":[{"id":"10.13039\/501100004082","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15131-7","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:45:33Z","timestamp":1764744333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Sojin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinkyo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyehyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousun","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"15131_CR1","unstructured":"The evolving treatment landscape. of metastatic urothelial cancer | Nature Reviews Urology [Internet]. [cited 2025 Feb 3]. Available from: https:\/\/www.nature.com\/articles\/s41585-024-00872-0?fromPaywallRec=false"},{"issue":"6","key":"15131_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, Santis MD, Huddart R, Loriot Y, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35(6):485\u201390.","journal-title":"Ann Oncol."},{"issue":"10064","key":"15131_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67\u201376.","journal-title":"Lancet"},{"issue":"7","key":"15131_CR4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SYS, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931\u201345.","journal-title":"Lancet Oncol"},{"key":"15131_CR5","doi-asserted-by":"publisher","unstructured":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. | New England Journal of Medicine [Internet]. [cited 2025 Feb 3]. Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2312117","DOI":"10.1056\/NEJMoa2312117"},{"issue":"19","key":"15131_CR6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778\u201389.","journal-title":"N Engl J Med"},{"issue":"11","key":"15131_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"15131_CR8","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2703","volume":"20","author":"H Guo","year":"2023","unstructured":"Guo H, Lin XY, Feng S, Wang C, Yuan LQ, Sheng XG, et al. Prognostic value of obesity in patients with cancer treated with immune checkpoint inhibitors: an updated meta\u2013analysis and systematic review. Mol Clin Oncol. 2023;20(1):5.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"15131_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","volume":"19","author":"JL McQuade","year":"2018","unstructured":"McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310\u201322.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15131_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-023-01532-4","volume":"14","author":"JE Park","year":"2023","unstructured":"Park JE, Jo J, Youk J, Kim M, Yoon SH, Keam B, et al. Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Insights Imaging. 2023;14(1):182.","journal-title":"Insights Imaging"},{"key":"15131_CR11","unstructured":"Weighing the role of skeletal muscle mass. and muscle density in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: a multicenter real-life study | Scientific Reports [Internet]. [cited 2025 Mar 28]. Available from: https:\/\/www.nature.com\/articles\/s41598-020-58498-2"},{"issue":"6","key":"15131_CR12","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1002\/jcsm.13367","volume":"14","author":"JH Lee","year":"2023","unstructured":"Lee JH, Kang D, Ahn JS, Guallar E, Cho J, Lee HY. Obesity paradox in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy. J Cachexia Sarcopenia Muscle. 2023;14(6):2898\u2013907.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"8018","key":"15131_CR13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41586-024-07529-3","volume":"630","author":"JE Bader","year":"2024","unstructured":"Bader JE, Wolf MM, Lupica-Tondo GL, Madden MZ, Reinfeld BI, Arner EN, et al. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature. 2024;630(8018):968\u201375.","journal-title":"Nature"},{"key":"15131_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102839","volume":"145","author":"GFP Aleixo","year":"2020","unstructured":"Aleixo GFP, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR. Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;145:102839.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"15131_CR15","first-page":"265","volume":"76","author":"EH Kim","year":"2021","unstructured":"Kim EH, Kim KW, Shin Y, Lee J, Ko Y, Kim YJ, et al. Reference data and T-scores of lumbar skeletal muscle area and its skeletal muscle indices measured by CT scan in a healthy Korean population. The Journals of Gerontology: Series A. 2021;76(2):265\u201371.","journal-title":"The Journals of Gerontology: Series A"},{"issue":"4","key":"15131_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/00004728-197710000-00016","volume":"1","author":"RA Brooks","year":"1977","unstructured":"Brooks RA. A quantitative theory of the Hounsfield unit and its application to dual energy scanning. J Comput Assist Tomogr. 1977;1(4):487\u201393.","journal-title":"J Comput Assist Tomogr"},{"issue":"6","key":"15131_CR17","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1016\/j.clnu.2021.04.017","volume":"40","author":"HK Kim","year":"2021","unstructured":"Kim HK, Kim KW, Kim EH, Lee MJ, Bae SJ, Ko Y, et al. Age-related changes in muscle quality and development of diagnostic cutoff points for myosteatosis in lumbar skeletal muscles measured by CT scan. Clin Nutr. 2021;40(6):4022\u20138.","journal-title":"Clin Nutr."},{"issue":"9403","key":"15131_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"Appropriate body-mass","year":"2004","unstructured":"Appropriate body-mass. Index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157\u201363.","journal-title":"Lancet"},{"issue":"6","key":"15131_CR19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3346\/jkms.2006.21.6.1048","volume":"21","author":"JA Kim","year":"2006","unstructured":"Kim JA, Choi CJ, Yum KS. Cut-off values of visceral fat area and waist circumference: diagnostic criteria for abdominal obesity in a Korean population. J Korean Med Sci. 2006;21(6):1048\u201353.","journal-title":"J Korean Med Sci"},{"key":"15131_CR20","doi-asserted-by":"publisher","unstructured":"New Criteria for \u2018Obesity Disease\u2019 in Japan. 2002. https:\/\/doi.org\/10.1253\/circj.66.987.","DOI":"10.1253\/circj.66.987"},{"issue":"1","key":"15131_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/bjc.2017.149","volume":"117","author":"M Ebadi","year":"2017","unstructured":"Ebadi M, Martin L, Ghosh S, Field CJ, Lehner R, Baracos VE, et al. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 2017;117(1):148\u201355.","journal-title":"Br J Cancer."},{"issue":"1","key":"15131_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.7570\/jomes24012","volume":"33","author":"SM Jeong","year":"2024","unstructured":"Jeong SM, Jung JH, Yang YS, Kim W, Cho IY, Lee YB, et al. 2023 obesity fact sheet: prevalence of obesity and abdominal obesity in adults, adolescents, and children in Korea from 2012 to 2021. J Obes Metab Syndr. 2024;33(1):27\u201335.","journal-title":"J Obes Metab Syndr"},{"key":"15131_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2021.111345","volume":"90","author":"HY Deng","year":"2021","unstructured":"Deng HY, Chen ZJ, Qiu XM, Zhu DX, Tang XJ, Zhou Q. Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: a comprehensive systematic review and meta-analysis. Nutrition. 2021;90:111345.","journal-title":"Nutrition"},{"issue":"6","key":"15131_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492\u20139.","journal-title":"Nat Immunol"},{"key":"15131_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2015.04.003","volume":"22","author":"JM Argil\u00e9s","year":"2015","unstructured":"Argil\u00e9s JM, Busquets S, Stemmler B, L\u00f3pez-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100\u20136.","journal-title":"Curr Opin Pharmacol."},{"key":"15131_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.clnesp.2024.08.015","volume":"63","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Guven DC. Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: a systematic review and meta-analysis. Clin Nutr ESPEN. 2024;63:829\u201336.","journal-title":"Clin Nutr ESPEN"},{"issue":"10","key":"15131_CR27","doi-asserted-by":"publisher","DOI":"10.2196\/23049","volume":"8","author":"DW Kim","year":"2020","unstructured":"Kim DW, Kim KW, Ko Y, Park T, Khang S, Jeong H, et al. Assessment of myosteatosis on computed tomography by automatic generation of a muscle quality map using a web-based toolkit: feasibility study. JMIR Med Inform. 2020;8(10):e23049.","journal-title":"JMIR Med Inform"},{"issue":"12","key":"15131_CR28","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/onco.13922","volume":"26","author":"DJ Martini","year":"2021","unstructured":"Martini DJ, Shabto JM, Goyal S, Liu Y, Olsen TA, Evans ST, et al. Body composition as an independent predictive and prognostic biomarker in advanced urothelial carcinoma patients treated with immune checkpoint inhibitors. Oncologist. 2021;26(12):1017\u201325.","journal-title":"Oncologist"},{"key":"15131_CR29","doi-asserted-by":"publisher","unstructured":"Paradoxical Effect of Myosteatosis on the Immune Checkpoint Inhibitor Response in Metastatic Renal Cell Carcinoma. - Yu \u2013\u20092025 - Journal of Cachexia, Sarcopenia and Muscle - Wiley Online Library [Internet]. [cited 2025 Apr 27]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/jcsm.13758","DOI":"10.1002\/jcsm.13758"},{"issue":"17","key":"15131_CR30","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1158\/1078-0432.CCR-16-3065","volume":"23","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, et al. Immuno-oncology trial endpoints: capturing clinically meaningful activity. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(17):4959\u201369.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"15","key":"15131_CR31","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1200\/JCO.23.00225","volume":"41","author":"M Merino","year":"2023","unstructured":"Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N. Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival. J Clin Oncol. 2023;41(15):2706\u201312.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15131-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T02:58:45Z","timestamp":1764903525000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15131-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15131"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15131-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Asan Medical Center (approval number: 2022\u2009\u2212\u20091692). The requirement for informed consent was waived by the Institutional Review Board of Asan Medical Center due to the retrospective nature of the study and the use of anonymized medical records only.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1853"}}